DABIGATRAN ETEXILATE EG LABO 110 mg, hard capsule 60 capsules
Active ingredients: DABIGATRAN ÉTEXILATE, MÉSILATE DE DABIGATRAN ÉTEXILATE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DABIGATRAN ETEXILATE EG LABO 110 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 6 plaquette(s) prédécoupées aluminium OPA : polyamide orienté PVC de 10 gélule(s)
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 22 Jan 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61492018CIP73026124CIP133400930261248Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DABIGATRAN ÉTEXILATEgélule | 110 mg · une gélule | FT |
| MÉSILATE DE DABIGATRAN ÉTEXILATEgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: DABIGATRAN ETEXILATE (MESILATE DE) équivalant à DABIGATRAN ETEXILATE 110 mg - PRADAXA 110 mg, gélule